AB Science SA
Deschisă
0.94 -0.95
Rezumat
Modificarea prețului
24h
Minim
0.914
Maxim
0.95
Venit | 8.8M 3.6M |
|---|---|
Vânzări | 144K 659K |
Marjă de profit | 549.317 |
Angajați | 36 |
EBITDA | 1.8M -727K |
Capitalizare de piață | -628K 68M |
|---|---|
Deschiderea anterioară | 1.89 |
Închiderea anterioară | 0.94 |
Scor tehnic
By Trading Central
Încredere
Bearish Evidence
AB Science SA Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
AB Science SA Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre AB Science SA
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
